FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033863232> ?p ?o ?g. }

• W3033863232 abstract "Abstract Background and Aims Secondary hyperparathyroidism is a common problem in patients undergoing chronic hemodialysis and its treatment includes vitamin D analogs and calcimimetics which act upon the calcium-sensing receptor. Etelcalcetide was introduced as an intravenous calcimimetic easy to administer at the end of the hemodialysis session with improved adherence. Hypocalcemic episodes have raised some concerns although this side effect is not unanimously described. As an institutional policy most patients from 2 hemodialysis units were switched from cinacalcet to etelcalcetide between July 2017 and January 2018. We aimed at evaluating the impact of this conversion upon laboratory values and ongoing medication. Method We collected data from patients in 2 hemodialysis units including monthly serum values of calcium, phosphorus, hemoglobin and albumin, quarterly parathormone (PTH) values from 3 months previous to conversion until 3 months post-conversion as well as the calcimimetic dose during the same time frame. Descriptive statistics concerning mean and median values of the previous 3 and next 3 months following conversion were used. A paired sample t-test was performed to compare values before and after conversion. Results Of the approximately 200 patients, 22 were on cinacalcet and were switched to etelcalcetide. These had a mean age of 66.9 years and included 9 women and 8 diabetics. Mean PTH value before conversion was 728±391 (range 371-1900pg/mL) and did not differ significantly from that after conversion 717±330 (p=0.9). No significant statistical difference between values before and after conversion was found for serum calcium (9.3±0.5 vs 9.2±0.6; p=0.43), phosphorus (5.4±0.8 vs 5.1±1.0; p=0.15), albumin (4.1±0.2 vs 4.1±0.2; p=0.83) and hemoglobin (11.3±0.8 vs 11.4±0.9; p=0.50). The mean number of hypocalcemic values during the 3 months before and after conversion was identical (0.6±1 vs 0.6±0.9; p=0.86). The median cinacalcet dose on the month before conversion was 30mg/day (IQR 22.5) and the median etelcalcetide dose at conversion was 2.5mg three times per week (IQR 1.9). The conversion factor was 27mg cinacalcet: 1mg etelcalcetide, because even patients on high cinacalcet doses were initially started at low etelcalcetide doses. However, at 3 months following conversion, the median etelcalcetide dose was 8.75 (IQR 7.5). The doses of erythropoiesis-stimulating agents (ESA), vitamin D analogues and phosphorus binders were not significantly affected. Conclusion Switching from cinacalcet to etelcalcetide in all patients on hemodialysis in a particular institution did not change laboratory values or increased the number of hypocalcemic measurements. The etelcalcetide dose was adjusted up for the first 3 months and the mean PTH value did not change significantly. Treatment with ESA, vitamin D analogues and phosphorus binders remained unchanged after conversion. Secondary hyperparathyroidism is a chronic condition and etelcalcetide provides a useful means to control it with an easy administration regimen." @default.
• W3033863232 created "2020-06-12" @default.
• W3033863232 creator A5059513015 @default.
• W3033863232 creator A5086554041 @default.
• W3033863232 date "2020-06-01" @default.
• W3033863232 modified "2023-09-23" @default.
• W3033863232 title "P1398EFFECTS OF CONVERTING FROM CINACALCET TO ETELCALCETIDE" @default.
• W3033863232 doi "https://doi.org/10.1093/ndt/gfaa142.p1398" @default.
• W3033863232 hasPublicationYear "2020" @default.
• W3033863232 type Work @default.
• W3033863232 sameAs 3033863232 @default.
• W3033863232 citedByCount "0" @default.
• W3033863232 crossrefType "journal-article" @default.
• W3033863232 hasAuthorship W3033863232A5059513015 @default.
• W3033863232 hasAuthorship W3033863232A5086554041 @default.
• W3033863232 hasConcept C126322002 @default.
• W3033863232 hasConcept C126894567 @default.
• W3033863232 hasConcept C141071460 @default.
• W3033863232 hasConcept C2775945674 @default.
• W3033863232 hasConcept C2778063415 @default.
• W3033863232 hasConcept C2778838027 @default.
• W3033863232 hasConcept C2780280601 @default.
• W3033863232 hasConcept C2780534505 @default.
• W3033863232 hasConcept C2781208988 @default.
• W3033863232 hasConcept C519063684 @default.
• W3033863232 hasConcept C71924100 @default.
• W3033863232 hasConceptScore W3033863232C126322002 @default.
• W3033863232 hasConceptScore W3033863232C126894567 @default.
• W3033863232 hasConceptScore W3033863232C141071460 @default.
• W3033863232 hasConceptScore W3033863232C2775945674 @default.
• W3033863232 hasConceptScore W3033863232C2778063415 @default.
• W3033863232 hasConceptScore W3033863232C2778838027 @default.
• W3033863232 hasConceptScore W3033863232C2780280601 @default.
• W3033863232 hasConceptScore W3033863232C2780534505 @default.
• W3033863232 hasConceptScore W3033863232C2781208988 @default.
• W3033863232 hasConceptScore W3033863232C519063684 @default.
• W3033863232 hasConceptScore W3033863232C71924100 @default.
• W3033863232 hasLocation W30338632321 @default.
• W3033863232 hasOpenAccess W3033863232 @default.
• W3033863232 hasPrimaryLocation W30338632321 @default.
• W3033863232 hasRelatedWork W10418522 @default.
• W3033863232 hasRelatedWork W10980105 @default.
• W3033863232 hasRelatedWork W13347795 @default.
• W3033863232 hasRelatedWork W13483695 @default.
• W3033863232 hasRelatedWork W1350366 @default.
• W3033863232 hasRelatedWork W1789652 @default.
• W3033863232 hasRelatedWork W20565001 @default.
• W3033863232 hasRelatedWork W3730576 @default.
• W3033863232 hasRelatedWork W4538660 @default.
• W3033863232 hasRelatedWork W7625368 @default.
• W3033863232 isParatext "false" @default.
• W3033863232 isRetracted "false" @default.
• W3033863232 magId "3033863232" @default.
• W3033863232 workType "article" @default.